Skip to main content
UniHealth

Doctor search

Kerri E Rieger, MD

Undefined Physician Type (Specify) · Pleasanton

NPI 1336333475

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
2

Offices

2 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Good Samaritan Hospital · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Rieger’s office to ask if they take your plan before you enroll.

California Medical Board record

Licence A101071 · Current

Licensed to practise in California · since 2007 · expires 2028-09-30 · Stanford University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

3 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend it
    Overall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital

Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Good Samaritan Hospital
Clostridium Difficile (C.Diff)Infections0.337BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.75 (0 to 1.67) · 1,340 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.84 (0.54 to 1.14)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths143.59 (98.7 to 188.49) · 98 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.7 · 45 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 100 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.7 · 270 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths11.3 · 573 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths15.6 · 820 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.5 · 482 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.3 · 3,711 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.12 (0 to 0.3) · 8,866 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.01 to 0.38) · 9,051 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.65 (0.74 to 4.56) · 1,929 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.8 (0.21 to 3.39) · 670 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.33 (0.88 to 3.78) · 1,836 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths6.73 (0 to 13.46) · 669 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths7.58 (3.96 to 11.19) · 654 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.59 (0.13 to 3.04) · 496 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.27 (0 to 0.87) · 7,373 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.1 · 152 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections1.08No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.542No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.484No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.565No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits15.8 · 327 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits24.2 · 703 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits61.1 · 289 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits36.3 · 665 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits25.4 · 856 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits19 · 978 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits6.3 · 144 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits12.3 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits21.2 · 135 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.8 (10.1 to 18.6) · 129 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (0.9 to 1.5) · 531 casesNo differentJan 2024 – Dec 2024

What patients said (704 patients answered, 24% of those asked)

Patient survey stars by topic at Good Samaritan Hospital
Cleanliness3
Nurse communication3
Doctor communication2
Communication about medicines2
Discharge information3
Overall hospital rating2
Quietness1
Recommend hospital3
Share of patients giving the best answer at Good Samaritan Hospital
Room was "always" clean66%
Nurses "always" communicated well75%
Doctors "always" communicated well71%
Staff "always" explained54%
Yes, staff "did" give patients this information83%
Yes, staff "did" give patients information about help after discharge81%
Doctors "always" explained things so they could understand66%
Doctors "always" listened carefully69%
Doctors "always" treated them with courtesy and respect78%
Patients who gave a rating of "9" or "10" (high)63%
Staff "always" explained new medications68%
Nurses "always" explained things so they could understand69%
Nurses "always" listened carefully73%
Nurses "always" treated them with courtesy and respect82%
"Always" quiet at night38%
"YES", patients would definitely recommend the hospital67%
Staff "always" explained possible side effects40%
Yes, staff "did" give patients information about possible symptoms86%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$274,523

Medicare paid this office $274,523 for 2,871 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Pathology examination of tissue using a microscope, intermediate complexity2,453$130,467$32
Special stained specimen slides to examine tissue, each additional procedure431$27,515$25
Special stained specimen slides to examine tissue, initial procedure513$21,303$31
Surgical pathology consultation and report on referred slides prepared elsewhere242$18,858$71
Microscopic genetic analysis of tumor, manual98$14,169$37
See all 22 services
Every Original Medicare service billed
Pathology examination of tissue using a microscope, intermediate complexity2,453$130,467$32
Special stained specimen slides to examine tissue, each additional procedure431$27,515$25
Special stained specimen slides to examine tissue, initial procedure513$21,303$31
Surgical pathology consultation and report on referred slides prepared elsewhere242$18,858$71
Microscopic genetic analysis of tumor, manual98$14,169$37
Special stained specimen slides to identify organisms including interpretation and report335$13,380$23
Antibody evaluation, each additional single antibody stain procedure81$8,766$25
Short return visit (20+ min)43$4,679$79
Return visit (30+ min)28$4,168$107
Biopsy of related skin growth, first growth34$3,880$86
Pathology examination of tissue using a microscope, moderately high complexity31$3,849$74
Antibody evaluation, initial single antibody stain procedure81$2,723$31
Destruction of precancer skin growth, 1 growth37$2,479$48
Surgical pathology consultation and report on referred material requiring preparation of slides30$2,306$77
Destruction of precancer skin growth, 15 or more growths12$2,268$126
Biopsy of related skin growth, each additional growth26$2,220$48
Pathology examination of tissue using a microscope, moderately low complexity202$2,190$9
Destruction of precancer skin growth, 2-14 growths34$1,953$7
Genetic sequencing localization, initial procedure40$1,772$39
New patient visit (30+ min)15$1,441$96
Genetic sequencing localization, each additional procedure22$820$30
Special stained specimen slides to examine tissue including interpretation and report21$258$10

Procedures Medicare counted

Procedure volume Medicare published
Removal of skin lesions139More than 77% of doctors who do this
Skin biopsy63More than 71% of doctors who do this

Who their Medicare patients are

2,871 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 16% · Women 47% · Also on Medicaid 11% · Health risk score 1.35. At or below the middle of the specialty; the typical undefined physician type clinician is at 1.67.

Conditions among them: High blood pressure 65% · Coronary heart disease 25% · Chronic kidney disease 23% · Cancer 22% · Diabetes 21% · Atrial fibrillation 19% · Heart failure 15% · Depression 14% · COPD 11% · Stroke 8% · Dementia 6%.

The office billed $3,437,264, Medicare allowed $362,164 and paid $274,523; for 8,616 services of 39 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242,8718,616761.35$3,437,264$274,523
20232,4737,102761.37$2,638,349$233,308
20222,4777,367761.32$2,305,710$241,706
20212,1076,106751.37$1,343,288$210,026
20201,6475,124751.39$1,093,856$178,257
20191,9906,041761.42$1,139,986$200,920
20182,0085,937751.36$1,057,376$188,589
20171,5254,022751.35$721,356$136,076
20161,4924,326751.40$753,323$140,706
20151,2913,879751.31$665,249$126,261
20141,2673,469751.27$621,506$111,625
20131,0452,619751.26$452,477$92,691

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 18 services

Original Medicare services billed in 2023
Pathology examination of tissue using a microscope, intermediate complexity2,095$117,614$32
Special stained specimen slides to examine tissue, each additional procedure336$20,363$26
Surgical pathology consultation and report on referred slides prepared elsewhere229$18,907$77
Special stained specimen slides to examine tissue, initial procedure416$17,672$31
Special stained specimen slides to identify organisms including interpretation and report297$12,375$24
Microscopic genetic analysis of tumor, manual59$8,285$39
Antibody evaluation, each additional single antibody stain procedure76$8,172$26
Short return visit (20+ min)39$4,957$83
Pathology examination of tissue using a microscope, moderately high complexity28$2,927$77
Antibody evaluation, initial single antibody stain procedure76$2,566$33
Surgical pathology consultation and report on referred material requiring preparation of slides31$2,529$82
Biopsy of related skin growth, first growth18$2,124$106
Destruction of precancer skin growth, 1 growth24$1,959$49
Return visit (30+ min)13$1,770$104
Pathology examination of tissue using a microscope, moderately low complexity150$1,609$10
Destruction of precancer skin growth, 2-14 growths23$1,560$6
Genetic sequencing localization, initial procedure22$949$40
Special stained specimen slides to examine tissue including interpretation and report17$322$11

2022: 20 services

Original Medicare services billed in 2022
Pathology examination of tissue using a microscope, intermediate complexity2,152$117,451$33
Special stained specimen slides to examine tissue, each additional procedure361$26,077$26
Special stained specimen slides to examine tissue, initial procedure428$18,156$32
Surgical pathology consultation and report on referred slides prepared elsewhere197$16,509$76
Special stained specimen slides to identify organisms including interpretation and report306$12,285$24
Antibody evaluation, each additional single antibody stain procedure89$9,435$26
Microscopic genetic analysis of tumor, manual66$8,734$39
Pathology examination of tissue using a microscope, moderately high complexity43$5,173$77
Short return visit (20+ min)40$4,435$78
Biopsy of related skin growth, first growth27$3,160$90
Antibody evaluation, initial single antibody stain procedure89$2,976$32
Surgical pathology consultation and report on referred material requiring preparation of slides31$2,458$79
Biopsy of related skin growth, each additional growth17$2,444$48
Return visit (30+ min)13$1,656$103
Pathology examination of tissue using a microscope, moderately low complexity142$1,591$10
Destruction of precancer skin growth, 1 growth25$1,447$37
Genetic sequencing localization, initial procedure32$1,387$41
Destruction of precancer skin growth, 2-14 growths19$1,089$6
Genetic sequencing localization, each additional procedure12$548$32
Special stained specimen slides to examine tissue including interpretation and report18$347$11

2021: 18 services

Original Medicare services billed in 2021
Pathology examination of tissue using a microscope, intermediate complexity1,801$102,875$34
Special stained specimen slides to examine tissue, each additional procedure246$22,774$27
Surgical pathology consultation and report on referred slides prepared elsewhere177$15,006$77
Special stained specimen slides to examine tissue, initial procedure327$14,140$33
Special stained specimen slides to identify organisms including interpretation and report264$11,005$25
Antibody evaluation, each additional single antibody stain procedure68$8,372$28
Microscopic genetic analysis of tumor, manual55$6,849$40
Short return visit (20+ min)45$4,909$85
Pathology examination of tissue using a microscope, moderately high complexity32$4,202$78
Surgical pathology consultation and report on referred material requiring preparation of slides33$2,705$82
Antibody evaluation, initial single antibody stain procedure68$2,642$34
Biopsy of related skin growth, first growth21$2,116$92
Return visit (30+ min)18$2,011$106
Genetic sequencing localization, initial procedure29$1,577$41
Destruction of precancer skin growth, 1 growth23$1,463$44
Pathology examination of tissue using a microscope, moderately low complexity116$1,372$10
Destruction of precancer skin growth, 2-14 growths20$903$6
Special stained specimen slides to examine tissue including interpretation and report22$343$11

2020: 18 services

Original Medicare services billed in 2020
Pathology examination of tissue using a microscope, intermediate complexity1,363$84,223$35
Special stained specimen slides to examine tissue, each additional procedure194$15,724$27
Surgical pathology consultation and report on referred slides prepared elsewhere175$15,145$77
Special stained specimen slides to examine tissue, initial procedure284$12,216$34
Special stained specimen slides to identify organisms including interpretation and report220$10,602$25
Antibody evaluation, each additional single antibody stain procedure80$9,430$28
Microscopic genetic analysis of tumor, manual65$6,679$41
Short return visit (20+ min)52$4,634$61
Surgical pathology consultation and report on referred material requiring preparation of slides37$3,169$83
Antibody evaluation, initial single antibody stain procedure79$2,970$35
Pathology examination of tissue using a microscope, moderately high complexity20$2,619$82
Destruction of precancer skin growth, 1 growth27$1,841$47
Biopsy of related skin growth, first growth19$1,362$65
Biopsy of related skin growth, each additional growth12$1,026$45
Genetic sequencing localization, initial procedure21$986$43
Destruction of precancer skin growth, 2-14 growths24$847$6
Pathology examination of tissue using a microscope, moderately low complexity68$778$10
Special stained specimen slides to examine tissue including interpretation and report25$492$12

2019: 18 services

Original Medicare services billed in 2019
Pathology examination of tissue using a microscope, intermediate complexity1,659$95,621$34
Special stained specimen slides to examine tissue, each additional procedure253$23,165$27
Special stained specimen slides to examine tissue, initial procedure369$16,339$33
Surgical pathology consultation and report on referred slides prepared elsewhere180$14,873$77
Special stained specimen slides to identify organisms including interpretation and report262$11,695$24
Antibody evaluation, each additional single antibody stain procedure84$8,893$27
Pathology examination of tissue using a microscope, moderately high complexity37$5,649$80
Microscopic genetic analysis of tumor, manual65$5,602$41
Short return visit (20+ min)54$3,789$49
Antibody evaluation, initial single antibody stain procedure84$3,170$34
Surgical pathology consultation and report on referred material requiring preparation of slides32$2,496$78
Destruction of precancer skin growth, 1 growth28$2,036$48
Pathology examination of tissue using a microscope, moderately low complexity105$1,180$10
Biopsy of related skin growth, first growth22$1,130$40
Biopsy of related skin growth, each additional growth13$604$26
Genetic sequencing localization, initial procedure14$587$39
Destruction of precancer skin growth, 2-14 growths27$452$3
Special stained specimen slides to examine tissue including interpretation and report12$229$11

2018: 20 services

Original Medicare services billed in 2018
Pathology examination of tissue using a microscope, intermediate complexity1,706$96,352$33
Special stained specimen slides to examine tissue, each additional procedure208$18,822$26
Special stained specimen slides to examine tissue, initial procedure374$15,858$32
Surgical pathology consultation and report on referred slides prepared elsewhere195$15,630$77
Special stained specimen slides to identify organisms including interpretation and report252$12,668$24
Antibody evaluation, each additional single antibody stain procedure64$6,705$26
Pathology examination of tissue using a microscope, moderately high complexity21$3,802$78
Microscopic genetic analysis of tumor, manual57$3,755$41
Short return visit (20+ min)47$2,460$38
Surgical pathology consultation and report on referred material requiring preparation of slides31$2,319$72
Antibody evaluation, initial single antibody stain procedure65$2,255$33
Destruction of precancer skin growth, 1 growth28$1,428$40
Pathology examination of tissue using a microscope, moderately low complexity103$1,050$10
Genetic sequencing localization, initial procedure20$978$41
Biopsy of single growth of skin and/or tissue30$837$24
Biopsy of each additional growth of skin and/or tissue19$588$17
Genetic sequencing localization, each additional procedure12$545$32
Destruction of precancer skin growth, 2-14 growths26$326$2
Examination of archival tissue for genetic analysis14$273$18
Special stained specimen slides to examine tissue including interpretation and report16$245$11

2017: 18 services

Original Medicare services billed in 2017
Pathology examination of tissue using a microscope, intermediate complexity1,248$70,641$34
Surgical pathology consultation and report on referred slides prepared elsewhere167$13,296$76
Special stained specimen slides to examine tissue, each additional procedure138$11,806$26
Special stained specimen slides to examine tissue, initial procedure235$10,880$32
Special stained specimen slides to identify organisms including interpretation and report178$7,527$25
Pathology examination of tissue using a microscope, moderately high complexity29$5,135$78
Antibody evaluation, each additional single antibody stain procedure37$3,907$26
Surgical pathology consultation and report on referred material requiring preparation of slides31$2,533$79
Short return visit (20+ min)39$1,676$34
Microscopic genetic analysis of tumor, manual20$1,617$51
Antibody evaluation, initial single antibody stain procedure37$1,440$33
New patient visit (30+ min)14$918$66
Destruction of precancer skin growth, 1 growth23$912$36
Pathology examination of tissue using a microscope, moderately low complexity69$726$10
Biopsy of single growth of skin and/or tissue18$496$26
Biopsy of each additional growth of skin and/or tissue11$307$19
Special stained specimen slides to examine tissue including interpretation and report13$207$11
Destruction of precancer skin growth, 2-14 growths19$143$2

2016: 18 services

Original Medicare services billed in 2016
Pathology examination of tissue using a microscope, intermediate complexity1,199$65,976$33
Special stained specimen slides to examine tissue, each additional procedure158$15,489$25
Surgical pathology consultation and report on referred slides prepared elsewhere165$13,141$77
Special stained specimen slides to examine tissue, initial procedure270$11,203$32
Special stained specimen slides to identify organisms including interpretation and report211$9,439$25
Antibody evaluation, each additional single antibody stain procedure53$4,750$25
Pathology examination of tissue using a microscope, moderately high complexity21$3,825$78
Surgical pathology consultation and report on referred material requiring preparation of slides46$3,529$77
Short return visit (20+ min)49$2,766$40
Microscopic genetic analysis of tumor, manual35$2,243$50
Antibody evaluation, initial single antibody stain procedure53$2,100$33
Destruction of precancer skin growth, 1 growth18$1,123$43
New patient visit (30+ min)16$998$62
Biopsy of single growth of skin and/or tissue23$955$33
Pathology examination of tissue using a microscope, moderately low complexity67$746$10
Biopsy of each additional growth of skin and/or tissue11$490$22
Special stained specimen slides to examine tissue including interpretation and report23$451$11
Destruction of precancer skin growth, 2-14 growths16$203$2

2015: 16 services

Original Medicare services billed in 2015
Pathology examination of tissue using a microscope, intermediate complexity1,031$58,326$33
Antibody evaluation, initial single antibody stain procedure59$11,761$38
Special stained specimen slides to identify organisms including interpretation and report215$10,826$25
Surgical pathology consultation and report on referred slides prepared elsewhere138$10,709$75
Special stained specimen slides to examine tissue, initial procedure234$9,504$32
Special stained specimen slides to examine tissue, each additional procedure119$8,785$19
Surgical pathology consultation and report on referred material requiring preparation of slides56$4,349$75
Pathology examination of tissue using a microscope, moderately high complexity22$2,885$74
Short return visit (20+ min)34$1,853$41
Microscopic genetic analysis of tumor, manual28$1,596$50
New patient visit (30+ min)21$1,207$57
Destruction of precancer skin growth, 1 growth21$1,023$43
Pathology examination of tissue using a microscope, moderately low complexity64$747$10
Biopsy of single growth of skin and/or tissue18$526$26
Special stained specimen slides to examine tissue including interpretation and report21$487$11
Destruction of precancer skin growth, 2-14 growths17$183$2

2014: 12 services

Original Medicare services billed in 2014
Pathology examination of tissue using a microscope, intermediate complexity1,024$56,579$33
Surgical pathology consultation and report on referred slides prepared elsewhere166$12,950$71
Special stained specimen slides to identify organisms including interpretation and report203$8,839$24
Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain210$7,658$27
Antibody evaluation, initial single antibody stain procedure37$7,359$39
Surgical pathology consultation and report on referred material requiring preparation of slides83$6,730$77
Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure)122$5,219$11
Pathology examination of tissue using a microscope, moderately high complexity19$2,585$76
Microscopic genetic analysis of tumor, manual27$1,566$49
Genetic sequencing localization, initial procedure11$969$54
Pathology examination of tissue using a microscope, moderately low complexity49$548$10
Special stained specimen slides to examine tissue including interpretation and report17$249$11

2013: 13 services

Original Medicare services billed in 2013
Pathology examination of tissue using a microscope, intermediate complexity827$41,215$32
Special stained specimen slides to examine tissue, initial procedure128$17,295$38
Surgical pathology consultation and report on referred slides prepared elsewhere128$10,864$73
Special stained specimen slides to identify organisms including interpretation and report162$7,514$23
Antibody evaluation, initial single antibody stain procedure23$4,337$38
Surgical pathology consultation and report on referred material requiring preparation of slides44$3,379$72
Short return visit (20+ min)38$1,810$36
Pathology examination of tissue using a microscope, moderately high complexity12$1,185$74
New patient visit (30+ min)17$970$57
Microscopic genetic analysis of tumor, manual16$888$47
Biopsy of single growth of skin and/or tissue19$702$33
Pathology examination of tissue using a microscope, moderately low complexity40$432$10
Special stained specimen slides to examine tissue including interpretation and report20$276$11

Medicaid work

$46,965 in 2024

Medicaid paid $46,965 for 1,250 billed services this clinician did in 2024, up to 95 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
TISSUE EXAM BY PATHOLOGIST718$27,631
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)221$9,210
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure101$3,840
TISSUE EXAM BY PATHOLOGIST108$3,274
IMHCHEM/IMCYTCHM EA ADD ANTB102$3,009
Medicaid work by year
20241,250595$46,965
20231,1935113$53,794
2022870573$36,569
2021677471$27,064
2020479358$20,312
2019549357$24,317
2018632352$27,364
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
TISSUE EXAM BY PATHOLOGIST774$34,980
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)204$9,764
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure105$5,488
TISSUE EXAM BY PATHOLOGIST82$2,514
IMHCHEM/IMCYTCHM EA ADD ANTB28$1,049

2022

Largest Medicaid services in 2022
TISSUE EXAM BY PATHOLOGIST597$23,729
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)164$6,226
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure57$4,254
IMHCHEM/IMCYTCHM EA ADD ANTB24$1,628
TISSUE EXAM BY PATHOLOGIST28$733

2021

Largest Medicaid services in 2021
TISSUE EXAM BY PATHOLOGIST487$18,923
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)149$5,436
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure28$1,765
IMHCHEM/IMCYTCHM EA ADD ANTB13$940

2020

Largest Medicaid services in 2020
TISSUE EXAM BY PATHOLOGIST376$15,885
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)84$3,663
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure19$763

2019

Largest Medicaid services in 2019
TISSUE EXAM BY PATHOLOGIST440$19,664
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure52$2,527
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)57$2,126

2018

Largest Medicaid services in 2018
TISSUE EXAM BY PATHOLOGIST499$22,018
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)119$4,918
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure14$428

Drugs they prescribed that Part D paid

$147,992

Pharmacies billed $147,992 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

105 generic and fewer than 11 brand-name prescriptions · $147,992 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Ketoconazole25$433$17
Hydrocortisone14$148$11

Year by year

Part D prescribing by year
202411524NoneNone$147,992
2023106300% (0)None$116,008
202272230% (0)None$159,046
2021102270% (0)12%$162,259
2020102240% (0)None$58,110
201960220% (0)None$118,462
201862290% (0)None$81,769
201779260% (0)None$5,161
201696360% (0)26%$8,250
201555180% (0)44%$6,199
201390310% (0)26%$5,193

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 4 drugs

Part D drugs prescribed in 2023
Fluocinonide14$836$60
Ketoconazole19$232$12
Triamcinolone Acetonide15$115$8
Hydrocortisone11$114$10

2022: 1 drug

Part D drugs prescribed in 2022
Hydrocortisone11$264$24

2021: 3 drugs

Part D drugs prescribed in 2021
Clobetasol Propionate11$540$49
Hydrocortisone17$247$15
Triamcinolone Acetonide14$133$9

2020: 3 drugs

Part D drugs prescribed in 2020
Fluocinonide14$792$57
Ketoconazole12$182$15
Triamcinolone Acetonide18$178$10

2017: 1 drug

Part D drugs prescribed in 2017
Desonide11$996$91

2016: 1 drug

Part D drugs prescribed in 2016
Fluocinonide19$1,942$102

2015: 2 drugs

Part D drugs prescribed in 2015
Desonide11$2,688$244
Methotrexate17$828$49

2013: 2 drugs

Part D drugs prescribed in 2013
Fluocinonide25$1,952$78
Ketoconazole19$374$20

Money from drug and device companies

$11,750 in 2023

Industry payments by year
202312$11,750$11,750
202211$4,978$4,978
202023$30,600$30,600
201918$7,500$8,704

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
PfizerNone$11,750
2 payments
  • Consulting · 2023-04-03 · $11,000
  • Consulting · 2023-04-03 · $750
See all 2 published payments
Every published payment
PfizerConsulting · 2023-04-03None$11,000
PfizerConsulting · 2023-04-03None$750
See earlier years (2022, 2020, 2019)

2022: $4,978

Payments by company in 2022
Kyowa KirinPoteligeo$4,978
1 payment
  • Honoraria for Poteligeo · 2022-12-20 · $4,978

2020: $30,600

Payments by company in 2020
Kyowa KirinSancuso$18,600
2 payments
  • Consulting for Sancuso · 2020-12-17 · $9,300
  • Consulting for Sancuso · 2020-12-17 · $9,300
PfizerNone$12,000
1 payment
  • Consulting · 2020-08-17 · $12,000

2019: $8,704

Payments by company in 2019
Kyowa KirinPoteligeo$8,704
8 payments
  • Travel for Poteligeo · 2019-11-02 · $696
  • Consulting for Poteligeo · 2019-11-02 · $7,500
  • Travel for Poteligeo · 2019-11-02 · $229
  • Meals for Poteligeo · 2019-11-02 · $48
  • Meals for Poteligeo · 2019-11-02 · $45
  • Meals for Poteligeo · 2019-11-02 · $50
  • Meals for Poteligeo · 2019-11-01 · $12
  • Meals for Poteligeo · 2019-11-01 · $125

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
PFIZER INC. · Pf07038124 Brepocitinib Dazukibart Pf06763809 Dekavil Pf06817024 Pf06480605 Ritlecitinib Zimlovisertib Pf06826647 Pf06835375 Multi Product Pf07054894 Pf06473871 Clinical Publication Program · 2024This clinician$3,200
PFIZER INC. · Brepocitinib Clinical Publication Program · 2023This clinician$330

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1336333475
Licence
CA A101071California A101071: Current · expires 2028-09-30
Trained
Stanford University School of Medicine, 2006
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207N00000X (207N00000X); Federal specialty code 207ND0900X (207ND0900X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2007-08-31
NPI last updated
2026-07-09
NPI record certified
2026-07-09

This is when the NPI record was last certified, not a medical board exam.